Evidence map›Paper›PMID 39057348›Full record

ArticleJournal of fungi (Basel, Switzerland)2024

Unmasking the Antifungal Activity of

Luis F Quejada, Andrea X Hernandez, Luis C Chitiva, Claudia P Bravo-Chaucanés, Yerly Vargas-Casanova, Robson X Faria, Geison M Costa, Claudia M Parra-Giraldo

Abstract read
In one paragraph

Article in Journal of fungi (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. In silico analysis ofIn silico pharmacology · 2026
    Article
  3. Article
  4. Antifungal Synergy: Mechanistic Insights into the R-1-R Peptide andInternational journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Luis F QuejadaUnidad de Proteómica y Micosis Humanas, Grupo de Enfermedades Infecciosas, Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, Carrera 7 No. 43-82, 110231 Bogotá, Colombia.ORCID 0000-0003-2348-4792
Andrea X HernandezGrupo de Investigación Fitoquímica Universidad Javeriana (GIFUJ), Departamento de Química, Facultad de Ciencias, Pontificia Universidad Javeriana, Carrera 7 No. 43-82, 110231 Bogotá, Colombia.
Luis C ChitivaGrupo de Investigación Fitoquímica Universidad Javeriana (GIFUJ), Departamento de Química, Facultad de Ciencias, Pontificia Universidad Javeriana, Carrera 7 No. 43-82, 110231 Bogotá, Colombia.ORCID 0000-0003-1422-5545
Claudia P Bravo-ChaucanésUnidad de Proteómica y Micosis Humanas, Grupo de Enfermedades Infecciosas, Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, Carrera 7 No. 43-82, 110231 Bogotá, Colombia.ORCID 0009-0003-6855-0770
Yerly Vargas-CasanovaUnidad de Proteómica y Micosis Humanas, Grupo de Enfermedades Infecciosas, Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, Carrera 7 No. 43-82, 110231 Bogotá, Colombia.ORCID 0000-0003-4788-8150
Robson X FariaLaboratório de Toxoplasmose e outras Protozooses, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz-FIOCRUZ, Rio de Janeiro 21045-900, RJ, Brazil.ORCID 0000-0001-8218-834X
Geison M CostaGrupo de Investigación Fitoquímica Universidad Javeriana (GIFUJ), Departamento de Química, Facultad de Ciencias, Pontificia Universidad Javeriana, Carrera 7 No. 43-82, 110231 Bogotá, Colombia.ORCID 0000-0003-2449-1986
Claudia M Parra-GiraldoUnidad de Proteómica y Micosis Humanas, Grupo de Enfermedades Infecciosas, Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, Carrera 7 No. 43-82, 110231 Bogotá, Colombia.

Funding

bank world contract No. FP44842-221-2018Convocatoria del Fondo de Ciencia, Tecnología e Innovación del Sistema General de Regalías, en el marco del Programa de Becas de Excelencia Doctoral del Bicentenario Segunda Convocatoria
6 · The paper itself

Abstract

Invasive fungal disease causes high morbidity and mortality among immunocompromised patients. Resistance to conventional antifungal drugs and the toxicity associated with high doses highlight the need for effective antifungal therapies. In this study, the antifungal potential of the ethanolic extract of

Indexed as

Anacardium occidentaleantifungal resistanceantifungal treatmentCandida albicansCandida aurisinvasive

Identifiers

PMID39057348
PMCPMC11277670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.